Crowdfunding & retail investment in biotech

01Overview and value chain

Markers: [EC: Retail investor protection & crowdfunding regulation | OECD: Bioeconomy policy & governance | Regulator: FDA (US), EMA (EU), NMPA (China)]

Crowdfunding and retail investment platforms let non-accredited individual investors fund early-stage biotech companies directly, either through conventional equity stakes under securities-crowdfunding exemptions or through blockchain-based tokenized intellectual property (IP-NFTs) issued by decentralized-science (DeSci) organizations. Wefunder, operating under the US Regulation Crowdfunding (Reg CF) exemption, hosted live 2026 raises for companies including Mahzi Therapeutics (gene therapy for Pitt Hopkins Syndrome and related rare neurodevelopmental disorders) and Eliaz Therapeutics (XGal-3, an apheresis device targeting sepsis). StartEngine, which can raise under both Reg CF and the larger Regulation A+ exemption (up to $75 million), has hosted campaigns for Eliaz Therapeutics and Frontier Bio, a developer of lab-grown human tissue models and tissue-engineered vascular grafts. Molecule, based in Switzerland, operates the leading DeSci infrastructure for tokenizing biotech intellectual property as IP-NFTs; its Molecule Protocol V2, launched in 2025, integrates these IP-backed tokens with traditional corporate equity as a new “real-world asset” class, and its Molecule Labs interface (launched mid-2025) gives researchers a data hub for managing tokenized IP directly. VitaDAO, a decentralized autonomous organization funding longevity research through onchain governance, has funded gene-therapy programs such as Artan Bio and pursues its own Healthspan XPRIZE research plan. In the UK, Crowdcube hosted a 2026 raise for Equisera, whose RiPR supercritical water-reforming technology converts biogenic and mixed waste into biomethane, hydrogen, captured CO2 and biochar. Republic, a global crowdfunding platform with more than 3 million investors since 2016, partnered with healthcare-focused equity-crowdfunding platform RedCrow to expand its healthcare and biotech investment offerings.

The key directions of crowdfunding and retail investment in biotech are:

1. Regulation Crowdfunding (Reg CF) equity raises: US biotech startups selling equity stakes directly to non-accredited retail investors under SEC exemptions, typically with minimum investments as low as $100.
2. Regulation A+ and larger retail raises: a bigger US exemption (up to $75 million) allowing more mature biotech companies to raise larger rounds from the retail public with lighter disclosure than a full IPO.
3. Decentralized science (DeSci) and IP-NFTs: tokenizing a lab’s intellectual property rights as blockchain assets, letting a DAO or individual token holders fund early research in exchange for a share of future IP value.
4. Cross-border European crowdfunding: platforms operating under the EU’s unified European Crowdfunding Service Providers (ECSP) license, letting a single campaign legally raise from retail investors across all EU member states.

Sectoral value chain

[Startup listing & legal/financial audit] ──> [Campaign marketing & community building] ──> [Equity sale / IP-NFT minting]
                                                                                                        │
                                                                                          (Escrow & investor compliance checks)
                                                                                                        │
     [Clinical/R&D progress & investor reporting] <─── [Capital deployment into lab operations] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• IP-NFT tokenization: converting a lab’s intellectual-property rights (data-sharing agreements, licenses) into blockchain tokens (commonly ERC-1155) that a DAO or individual can buy, sell or hold as a claim on future IP value.
• Reg CF/Reg A+ smart-contract escrow: automated systems that hold investor funds until a campaign’s minimum funding target (“soft cap”) is met, distributing equity or refunding 100% of funds if the target is missed.
• DAO token governance: token-holder voting mechanisms that let a decentralized community decide which research projects a DeSci organization funds, in effect crowdsourcing grant review.

02US

The United States hosts the largest and most active biotech Reg CF/Reg A+ crowdfunding platforms, funding companies across gene therapy, medical devices and tissue engineering.

Wefunder’s Reg CF biotech raises, StartEngine’s Reg A+ scale, Republic’s healthcare-crowdfunding partnership

• Wefunder: hosted live 2026 Reg CF campaigns for companies including Mahzi Therapeutics (gene therapy for Pitt Hopkins Syndrome and related rare neurodevelopmental disorders) and Eliaz Therapeutics (its XGal-3 apheresis device targeting sepsis via Galectin-3 removal).
• StartEngine: able to raise under the larger Regulation A+ exemption (up to $75 million) in addition to Reg CF, has hosted campaigns for Eliaz Therapeutics and Frontier Bio, a developer of lab-grown human tissue models and tissue-engineered vascular grafts intended as safer preclinical alternatives to animal studies.
• Republic: a global crowdfunding platform with more than 3 million investors since its 2016 founding, partnered with healthcare-focused equity-crowdfunding platform RedCrow to expand its healthcare and biotech investment offerings to retail investors.

03CN

China permits state-supervised crowd-investment cooperatives for early-stage innovation while prohibiting cryptocurrency-based DeSci funding structures outright.

State-supervised crowd-investment platforms, Beijing Stock Exchange feeder pipeline, prohibition on crypto-based DeSci

• Government-backed crowd-investment platforms: Chinese authorities operate specialized crowd-investment platforms, supervised by the People’s Bank of China and the Ministry of Science and Technology, that let individuals invest small sums into cooperative-style science and technology vehicles supporting early-stage agri-biotech and green-chemistry teams, with tax incentives for participants.
• Beijing Stock Exchange feeder pipeline: crowdfunding campaigns function as an early screening mechanism that surfaces promising startups for a subsequent streamlined listing on the Beijing Stock Exchange, which was established specifically to support high-tech small and medium enterprises.
• Prohibition on crypto-based DeSci: China maintains an absolute ban on cryptocurrency-based fundraising structures, including DeSci-style token or IP-NFT models used elsewhere, treating unlicensed biotech fundraising schemes as a criminal offense; no specific China-based crowdfunding platform comparable to the US/EU companies profiled here could be confirmed via a live 2026 source.

04EU

The European Union’s unified crowdfunding license lets a single campaign legally raise from retail investors across all EU member states, while Switzerland anchors the region’s DeSci infrastructure.

Crowdcube’s ECSP-licensed cross-border raises, Molecule’s IP-NFT protocol, VitaDAO’s onchain longevity funding

• Crowdcube (UK): operating under the EU’s unified European Crowdfunding Service Providers (ECSP) license, hosted a 2026 raise for Equisera, whose RiPR supercritical water-reforming technology converts biogenic and mixed waste into biomethane, hydrogen, captured CO2 and biochar.
• Molecule (Switzerland): operates the leading DeSci infrastructure for tokenizing biotech intellectual property as IP-NFTs; its Molecule Protocol V2, launched in 2025, integrates these IP-backed tokens with traditional corporate equity as a new “real-world asset” class, and its Molecule Labs interface (mid-2025) gives researchers a direct data hub for managing tokenized IP.
• VitaDAO (Switzerland-anchored): a decentralized autonomous organization funding longevity research through onchain governance, has funded gene-therapy programs including Artan Bio and pursues its own dedicated Healthspan XPRIZE research plan.

05Leading companies and research institutes

06Tech stack and innovations

The biotech crowdfunding and DeSci stack pairs securities-compliance technology with blockchain infrastructure for tokenizing early-stage research assets:

1. IP-NFT tokenization:
   • A lab’s intellectual-property rights and data-sharing agreements are converted into blockchain tokens (commonly ERC-1155), letting a DAO or individual investor hold a claim on future licensing value without a traditional equity structure.
2. Reg CF/Reg A+ compliant escrow automation:
   • Smart-contract or platform-managed escrow systems hold investor funds until a campaign’s minimum funding target is met, automatically distributing shares or refunding all capital if the target is missed, removing manual reconciliation risk.
3. DAO token governance for grant allocation:
   • Token-holder voting mechanisms let a distributed community of retail backers decide which research proposals a DeSci organization funds, replacing a centralized grant committee with crowdsourced peer review.

07Value chains and production pipelines

Industrial pipeline for a Reg CF equity crowdfunding campaign for a biotech device startup

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Legal/financial audit   │ ───> │ 2. Campaign creation on    │
│    & Form C preparation        │      │    crowdfunding platform       │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Closing & AML/KYC       │ <─── │ 3. Public campaign launch  │
│    compliance check            │      │    & community marketing      │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Capital deployment      │ ───> │ 6. Quarterly investor      │
│    into R&D operations         │      │    reporting                   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Legal/financial audit and Form C preparation

The company completes an independent financial review or full GAAP audit of the past two years and its legal counsel prepares the SEC’s required Form C disclosure document ahead of filing.

Stage 2: Campaign creation on crowdfunding platform

The startup builds its campaign page on the chosen platform, including a product demo video, investment tiers with a minimum check size, and an initial private pre-sale for its existing community.

Stage 3: Public campaign launch and community marketing

The campaign opens to the general retail investor public, supported by live demonstrations, founder Q&A sessions on community channels, and ongoing marketing to build momentum toward the funding target.

Stage 4: Closing and AML/KYC compliance check

Once the campaign reaches its target (or the campaign period ends), each investor is verified against anti-money-laundering and know-your-customer rules before funds are released from escrow.

Stage 5: Capital deployment into R&D operations

Raised capital is deployed into shared wet-lab rental, reagent purchases and engineering hires needed to advance the company’s product toward its next development milestone.

Stage 6: Quarterly investor reporting

The company provides its retail shareholder base with regular video or written updates on R&D progress, keeping investors informed ahead of a potential follow-on raise or later-stage venture round.